A user shared progress pictures after 5 months of using finasteride, noting hair growth and minimal side effects. They suggested adding minoxidil for further hair growth if needed.
The conversation discusses hair regrowth progress from Norwood scale 4 to 2.5 over a year using daily 8.5-9% RU58841, topical Dutasteride 0.1%, RU58841 5% 1.5 times a week, and daily caffeine redensyl scalp treatment.
A user shared their positive experience using topical finasteride and minoxidil for nine months to combat male pattern baldness, reporting healthier and thicker hair without side effects. They recommend these treatments but advise researching potential side effects and consulting a professional.
The post is about a user's 8-month progress after a hair transplant at Attica Clinic using 1400 grafts, oral Biotin, Pura D'or Serum, Klorane Quinine Shampoo, microneedling, and daily 5-minute scalp massages. The comments vary, with some praising the results and others criticizing them as unnatural.
The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.
There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.
Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.
RU58841 can be ordered as a powder and compounded at home, but it should be stored at room temperature to avoid crystallization. Pyraulatmide may follow a similar principle.
A 16-year-old female experiencing severe hair loss and sebum buildup, likely due to telogen effluvium and PCOS, is currently using vitamin D3 supplements, Redenser serum, and T follihair supplements. Recommendations include addressing PCOS first and consulting a doctor.
The conversation is about hair loss treatments, specifically the anticipation for the release of a new treatment, GT20029, by 2028. Users are discussing their experiences with current treatments like finasteride and dutasteride, and the potential of future treatments, including FAK inhibitors and verteporfin trials.
The user shared progress pictures after 10 months of using topical finasteride and minoxidil, along with dermarolling and specific shampoos. Some users suggested switching to oral treatments for better results, while others noted visible improvements in hair thickness and regrowth.
The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.
GeneTherica is discussed as a source for RU58841, with ordering possible via WhatsApp. The conversation focuses on the legitimacy of this supplier for hair loss treatment.
A user's 6-month update on their hair loss treatment regimen, which includes finasteride, minoxidil and derma rolling, with no significant side effects.
The user is experiencing hair shedding after using minoxidil and is considering switching to dutasteride while planning to increase their oral minoxidil dose. They also use nicotine pouches, Vyvanse, and GHK-Cu, and have noticed thicker eyebrows and lashes from oral minoxidil.
The conversation is about seeking updates on the hair loss treatment RCH-01, specifically its next phase and any news from Shiseido. The user recalls someone being in contact with a researcher or company representative.
J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."
The user experienced rapid diffuse hair thinning for five years despite no signs of AGA or miniaturization. They tried finasteride and oral minoxidil without success and have checked thyroid, iron, and vitamin D levels.
The conversation is about using vitamin C and Magnesium L-Threonate for hair growth by reducing DHT binding to dermal papilla cells. The original post about vitamin C's pH levels and sebum control was possibly removed by a moderator.
A user experienced initial success with finasteride, noticing reduced hair fall and stronger hair, but later faced a heavy shedding phase. The shedding has since slowed, and they are seeking advice on what to do next.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.
A 31-year-old woman shared her 9-month progress using 5% minoxidil foam for hair loss, noting significant improvement after initial shedding and seeing regrowth by month 4. She also used ketoconazole shampoo and has been on spironolactone for acne, but did not use finasteride.
The user experienced hair thinning from chromium and alpha lipoic acid supplements, which stopped after discontinuing them. Someone mentioned this could be telogen effluvium, a temporary condition.
The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
People are discussing JXL-069 (PP405) for hair loss, with some experimenting with a 0.05% topical gel. Concerns about safety and efficacy persist due to limited testing and lack of official approval.
The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.